Suppr超能文献

S100A2与KPNA2之间的相互作用介导NFYA入核,是结直肠癌转移的一个新的治疗靶点。

The interaction between S100A2 and KPNA2 mediates NFYA nuclear import and is a novel therapeutic target for colorectal cancer metastasis.

作者信息

Han Fengyan, Zhang Lei, Liao Shaoxia, Zhang Yanmin, Qian Lili, Hou Feijun, Gong Jingwen, Lai Maode, Zhang Honghe

机构信息

Department of Pathology and Women's Hospital, Zhejiang University School of Medicine, Research Unit of Intelligence Classification of Tumor Pathology and Precision Therapy, Chinese Academy of Medical Sciences (2019RU042), Hangzhou, 310058, Zhejiang, China.

Key Laboratory of Disease Proteomics of Zhejiang Province, Hangzhou, 310058, Zhejiang, China.

出版信息

Oncogene. 2022 Jan;41(5):657-670. doi: 10.1038/s41388-021-02116-6. Epub 2021 Nov 20.

Abstract

Nucleocytoplasmic transport of proteins is disrupted and dysregulated in cancer cells. Nuclear pore complexes and cargo proteins are two main transportation regulators. However, the mechanism regulating nucleocytoplasmic transport in cancer remains elusive. Here, we identified a S100A2/KPNA2 cotransport complex that transports the tumor-associated transcription factor NFYA in colorectal cancer (CRC). Through the S100A2/KNPA2 complex, depending on its interaction with S100A2, NFYA is transported to the nucleus and inhibits the transcriptional activity of E-cadherin, which in turn promotes CRC metastasis. Targeting the S100A2/KPNA2 binding sites with the specific inhibitor delanzomib is a potential therapeutic approach for CRC.

摘要

蛋白质的核质运输在癌细胞中被破坏且失调。核孔复合体和货物蛋白是两个主要的运输调节因子。然而,癌症中调节核质运输的机制仍然不清楚。在这里,我们鉴定出一种S100A2/KPNA2共运输复合体,其在结直肠癌(CRC)中运输肿瘤相关转录因子NFYA。通过S100A2/KNPA2复合体,NFYA依赖于其与S100A2的相互作用被转运至细胞核,并抑制E-钙黏蛋白的转录活性,进而促进结直肠癌转移。用特异性抑制剂delanzomib靶向S100A2/KPNA2结合位点是一种潜在的结直肠癌治疗方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验